Recently, "2023 China Brand Value Evaluation Activity" initiated by China Brand Building Promotion Association, China Asset Appraisal Association and other organizations released the final evaluation results in Deqing, Zhejiang Province, and Yichang Renfu Pharmaceutical ranked eighth in the pharmaceutical and health group, with a brand strength of 884 and a brand value of 9.54 billion yuan, which was again improved by two places compared with the previous year. The brand value is 9.54 billion yuan, which is upgraded again compared with the previous year.
　　The public welfare "China Brand Value Evaluation Information Release" jointly organized by China Association for the Promotion of Brand Building and relevant authoritative units has lasted for ten years, which is an important initiative to establish a brand value evaluation mechanism with Chinese characteristics, create positive energy for Chinese brands and promote Chinese brands to the world. Following international and national standards and adhering to the working principles of "science, fairness, openness and recognition", the "China Brand Value Evaluation Information Release" has gained more and more attention and recognition from the society, and has also proved the fruitful achievements of China's brands in promoting the process of high-quality development.
　　This year, the number of participating brands reached 1,068, covering most of the leading enterprises in the industry, with 21 brands valued at more than 100 billion yuan. The company has participated in the brand value evaluation for four consecutive years, and the company's brand value and ranking in similar industries have reached record high every year. In the future, the company will continue to cast the brand with quality, promote development with brand, and continue to contribute to the protection of public health.